Boosting performance with an inclusive performance culture
Boosting performance of organizations with an inclusive performance culture
Search
Improving Access to Healthcare
According to the UN Sustainable Development Goals, almost half of the global population is not covered by essential health services.
Boehringer Ingelheim reaches more patients than ever in 2022 as innovative medicines drive growth
Boehringer Ingelheim today reported a strong performance in 2022
Ingelvac CircoFLEX
For the active immunisation of pigs over the age of two weeks against porcine circovirus type 2 to reduce mortality, clinical signs – including weight loss – and lesions in lymphoid tissues associated with porcine circovirus diseases (PCVD).
1990-2022: Value through Innovation
The Boehringer Ingelheim history from 1990 to 2022, with milestones
COVID-19 Q&A for Patients
Boehringer Ingelheim sees positive business momentum in 2020 despite impact of COVID-19
Boehringer Ingelheim sees positive business momentum in 2020 despite impact of COVID-19
Boehringer Ingelheim inaugurates new milestone on its long-term commitment to the Kingdom
Boehringer Ingelheim inaugurates new milestone on its long-term commitment to the Kingdom
2019 performance: stronger foundation to absorb global effects of COVID-19 pandemic
2019 performance: stronger foundation to absorb global effects of COVID-19 pandemic
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
In 2023, Boehringer Ingelheim in India, Middle East, Turkey and Africa (IMETA) region achieved net sales of EUR 779 million, reflecting a 13% increase compared to the previous year.
Advancing regenerative medicine
Strategic partnerships play a key role in helping the company accelerate the next generation of breakthroughs.
Good business performance gives Boehringer Ingelheim tailwind for investment in R&D
Good business performance gives Boehringer Ingelheim tailwind for investment in R&D
“Rapid progress towards clinical candidates”
Boehringer Ingelheim forms a joint venture to create the next generation of antimicrobials.
Clinical Trial Demonstrates Positive Top-Line Results Reducing Risk Cardiovascular
Clinical Trial Demonstrates Positive Top-Line Results in Reducing the Risk for Cardiovascular Death or Hospitalisation due to Heart Failure
Boehringer Ingelheim Opens New Scientific Office in Kenya as Part of its Commitment to Improve Human and Animal Health in Africa
Boehringer Ingelheim has officially opened its new scientific office in Nairobi, Kenya.
Innovation Prize Winners
Find out more about the winners of our Innovation Prize in Boston, New York and San Diego in the USA; Tokyo Japan and Vienna, Austria
Regional experts highlight need for coordinated, collaborative efforts in stroke care through
Regional experts highlight need for coordinated, collaborative efforts in stroke care through dedicated hospital unitsRegional experts highlight need for coordinated, collaborative efforts in stroke care through dedicated hospital units
COVID-19 General Q&A
COVID-19 General Q&A
10 tips cat friendly veterinary clinics
Here are 10 simple steps you can take to make feline patients feel at ease at your practice.
Oncology and Cancer Immunology Research
Find out more about our research and development in oncology and cancer immunology.
Scleroderma Life Hacks
Video series featuring people living with scleroderma using everyday items in different ways to help them manage their symptoms. Part of the global 'More Than Scleroderma' initiative developed by Boehringer Ingelheim, with support from patient organi
History of the logo
Overview of the history of the corporate logo of Boehringer Ingelheim, from the founding years of the company until today
Different life stages dogs preventive health
What does your dog need to thrive at every age? Get some tips here!
Fabio Paganini fostering inclusion & agility in AH
How employees are contributing to an inclusive culture at Boehringer Ingelheim.
Contact us
Find all our contact information here about our BD&L team.